PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NW\DO4tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX2fllKSzVyPUCuNFIzPzZizszN MWrTRW5ITVJ?
CHP-212 NXm4[lZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XlU2lEPTB;MD6wNlg5PSEQvF2= NHTJSIlUSU6JRWK=
EoL-1-cell NYXo[m5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{noSWlEPTB;MD6wOFE2OiEQvF2= M2q0cnNCVkeHUh?=
DU-4475 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMVZRKSzVyPUCuNFc2QTlizszN MVvTRW5ITVJ?
MMAC-SF NVTybVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWryS2xWUUN3ME2wMlExQTd2IN88US=> M1e2WHNCVkeHUh?=
AGS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7jTWM2OD1yLkGxO|E{KM7:TR?= MXrTRW5ITVJ?
M14 M2DmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOzTWM2OD1yLkG1OFY5KM7:TR?= NE\RdodUSU6JRWK=
CP50-MEL-B M1HUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMUeyOVQh|ryP M4Lv[nNCVkeHUh?=
C32 M1faOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUmwO|Ih|ryP NWfkS2FGW0GQR1XS
KMOE-2 NYO4d5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3kTWM2OD1yLkG5O|k2KM7:TR?= NYTDfllYW0GQR1XS
A101D NGPwVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMkG0JO69VQ>? MXnTRW5ITVJ?
KM12 NGnrPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITEPHhKSzVyPUCuNlQxPTdizszN NWLv[2VbW0GQR1XS
HSC-4 NVjmSHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMkSzPVUh|ryP M4X3bnNCVkeHUh?=
NOMO-1 NUC2RYRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIexTHRKSzVyPUCuNlU4PDJizszN NU\xUmZZW0GQR1XS
MZ7-mel MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor1TWM2OD1yLkK2N|Qh|ryP Mon6V2FPT0WU
ACN NHLMd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMk[3N|ch|ryP NI[4V2lUSU6JRWK=
MEL-HO M4\yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW2TWM2OD1yLkK3OlUzKM7:TR?= MmTrV2FPT0WU
BHT-101 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFTWM2OD1yLkK4OlA3KM7:TR?= NXfJVHFrW0GQR1XS
SK-MEL-28 NXXMPZBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknUTWM2OD1yLkOwOFA6KM7:TR?= NInzTppUSU6JRWK=
KG-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGyWoFKSzVyPUCuN|A3PjhizszN MnGzV2FPT0WU
COLO-679 NXHX[JdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLHTWM2OD1yLkOyO|Ih|ryP M13TenNCVkeHUh?=
SK-MEL-24 NFfC[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsXYVKSzVyPUCuN|I5OTNizszN NWLBS|V3W0GQR1XS
G-361 NFm3OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7SRmJKSzVyPUCuN|Y4QTVizszN M4W1VnNCVkeHUh?=
KY821 NEjQdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwM{e5NUDPxE1? NInyTHBUSU6JRWK=
KASUMI-1 M{HWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwM{m5JO69VQ>? M{LibnNCVkeHUh?=
HL-60 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNEGxNFch|ryP MkXpV2FPT0WU
K5 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPWV3BKSzVyPUCuOFMyOTdizszN NHPmS|BUSU6JRWK=
KU812 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[xPGlEPTB;MD60OVI6QSEQvF2= MoHrV2FPT0WU
SH-4 MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNE[yOVYh|ryP NFnKWIxUSU6JRWK=
HTC-C3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPreGpOUUN3ME2wMlQ3PTNzIN88US=> NITZNlNUSU6JRWK=
CP66-MEL NXHtO|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNEi4NFkh|ryP NFfqSVBUSU6JRWK=
WM-115 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xTWM2OD1yLkS5NlU4KM7:TR?= NWLzXGhJW0GQR1XS
A2780 NFS2TYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TOZWlEPTB;MD60PVgzOyEQvF2= MWrTRW5ITVJ?
P12-ICHIKAWA NV[zb4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq0UXNKSzVyPUCuOlEzOjFizszN M{W3NHNCVkeHUh?=
HMV-II M4TpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhTWM2OD1yLk[0OFY2KM7:TR?= NUPS[o1OW0GQR1XS
HT-144 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:3dGlEPTB;MD62OFY2PyEQvF2= NX2zXG51W0GQR1XS
LB2518-MEL NYfafZExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\pU|Q1UUN3ME2wMlcyPjN{IN88US=> MlPxV2FPT0WU
NCI-SNU-1 NEXmPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrYTWM2OD1yLke1OFM{KM7:TR?= MoOwV2FPT0WU
C2BBe1 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33aO2lEPTB;MD64NVAzOyEQvF2= NHTJdnNUSU6JRWK=
PSN1 NFfvOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwOU[xPVYh|ryP MnvZV2FPT0WU
UACC-257 NGn0V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq1TWM2OD1yLkm2OFc{KM7:TR?= M3r1O3NCVkeHUh?=
RVH-421 M2HwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1yLkm3NVgh|ryP M1PBUnNCVkeHUh?=
GP5d NXzyWGU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3xe5lnUUN3ME2wMlk5OzB6IN88US=> M17hd3NCVkeHUh?=
TYK-nu NYHFV|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jhZmlEPTB;MT6wN|E4OiEQvF2= NYLJW5ZmW0GQR1XS
SK-N-AS M2nQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMEe5OFch|ryP MnLhV2FPT0WU
SW620 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T4VGlEPTB;MT6xN|U{PCEQvF2= NWLoR5lzW0GQR1XS
HuP-T4 M3HKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1zLkG4N|U6KM7:TR?= M3fFdHNCVkeHUh?=
A549 NE\LZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KxWWlEPTB;MT6xPVU4PiEQvF2= MlnMV2FPT0WU
Mewo NXLBVZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMkCyO|Yh|ryP MVLTRW5ITVJ?
ONS-76 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPRcG0{UUN3ME2xMlIzODR7IN88US=> NX3zbJhLW0GQR1XS
SK-MEL-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwMkO0NVkh|ryP MV;TRW5ITVJ?
RCM-1 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WzdmlEPTB;MT6yOFA1PyEQvF2= MY\TRW5ITVJ?
H-EMC-SS NHnje2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\GOmlEPTB;MT6yPVYxQCEQvF2= M2rrN3NCVkeHUh?=
NCI-H2291 NGXrUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHmTWM2OD1zLkOyOVM3KM7:TR?= MWHTRW5ITVJ?
SW1463 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vaU2lEPTB;MT6zN|czOSEQvF2= MXLTRW5ITVJ?
LS-411N M{\2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37BeGlEPTB;MT60NFUyPyEQvF2= MUXTRW5ITVJ?
BV-173 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH6fHBKSzVyPUGuOFQxOTVizszN MX;TRW5ITVJ?
LS-513 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDvdI53UUN3ME2xMlQ2OTl{IN88US=> MUXTRW5ITVJ?
LoVo NFHsem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHhTYhKSzVyPUGuOFY{QTlizszN MofBV2FPT0WU
HO-1-N-1 M{XkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhOGlEPTB;MT61NVY{PCEQvF2= MmK4V2FPT0WU
ML-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDlbopKSzVyPUGuOVI5PjhizszN MWPTRW5ITVJ?
NCI-H1437 M3i4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiy[2VKSzVyPUGuOVUzPzVizszN M1e2WnNCVkeHUh?=
SW1116 M4Twfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNU[zPVgh|ryP MUnTRW5ITVJ?
A4-Fuk MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XQZ2lEPTB;MT61O|A1PSEQvF2= MnnOV2FPT0WU
HD-MY-Z NELhN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknwTWM2OD1zLkW3N|c3KM7:TR?= NWHYfphYW0GQR1XS
SK-MEL-2 NHmxTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTGb45UUUN3ME2xMlU4PDV7IN88US=> Moq0V2FPT0WU
RT-112 M3fnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjrdGcyUUN3ME2xMlU5QTV{IN88US=> NES0Z2tUSU6JRWK=
COLO-829 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13q[2lEPTB;MT62NlI{OiEQvF2= NHvYXpFUSU6JRWK=
OVCAR-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[2TWM2OD1zLke3Olg4KM7:TR?= M4OyPXNCVkeHUh?=
NB69 NWi2SFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vRdWlEPTB;MT63PFQ3QSEQvF2= NXi0UXRnW0GQR1XS
NCI-H292 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwOE[2PVkh|ryP NFnDfFVUSU6JRWK=
LOXIMVI NUexOmxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jNPGlEPTB;MT64PVQzPyEQvF2= MXnTRW5ITVJ?
BPH-1 M2\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwOEm1PVEh|ryP MV\TRW5ITVJ?
A375 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLJclhFUUN3ME2xMlg6PzF2IN88US=> MXLTRW5ITVJ?
LCLC-97TM1 Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC2VWViUUN3ME2xMlkzOjV4IN88US=> NFXv[nJUSU6JRWK=
RXF393 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfQU|BOUUN3ME2xMlk4QDh5IN88US=> MV;TRW5ITVJ?
HCC70 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwMEK0NlYh|ryP MXXTRW5ITVJ?
EM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpXGlEPTB;Mj6wO|E6QCEQvF2= NUSzbHlYW0GQR1XS
MZ2-MEL NWTCSoZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\wRpk3UUN3ME2yMlEyOTJ5IN88US=> MmHWV2FPT0WU
HN M3LWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD4TWM2OD1{LkG2Nlc5KM7:TR?= NXvVTpJGW0GQR1XS
A2058 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLnTWM2OD1{LkG5Nlc6KM7:TR?= M3O5OXNCVkeHUh?=
NB7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvnXmZKSzVyPUKuN|QxQDZizszN MXvTRW5ITVJ?
DOK NIPUdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwM{W3O|Mh|ryP MkTWV2FPT0WU
CAL-27 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwM{myN|Yh|ryP NH3o[3dUSU6JRWK=
BB65-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGryNFdKSzVyPUKuOFA3PzRizszN MVHTRW5ITVJ?
RD MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwNES3NlMh|ryP MlXjV2FPT0WU
KNS-62 NVjhOlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TZNmlEPTB;Mj61NVE3PCEQvF2= NYftfXZIW0GQR1XS
EW-13 M{\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj2TWM2OD1{LkW2N|M6KM7:TR?= MXPTRW5ITVJ?
DB NX7WOFVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nwNGlEPTB;Mj61PFc5QCEQvF2= M1\XdHNCVkeHUh?=
HCC2218 NFfLe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwNkS3O|gh|ryP Mnr5V2FPT0WU
L-363 NHPkeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTaTWM2OD1{Lke0N|ch|ryP NEX2RnpUSU6JRWK=
CHL-1 NGK0T|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLSO2ZrUUN3ME2yMlgxPzh3IN88US=> NFTOR4NUSU6JRWK=
BFTC-905 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHHV3pVUUN3ME2yMlgzPTNizszN M4LmRnNCVkeHUh?=
HCE-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrwTWM2OD1{LkizNlY1KM7:TR?= MlvaV2FPT0WU
COLO-792 M1XQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TVXGlEPTB;Mj64OFAzPyEQvF2= NI\Ge|JUSU6JRWK=
LB2241-RCC M172O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf5UmV{UUN3ME2yMlg2QDl|IN88US=> NVHhUG9ZW0GQR1XS
CAL-39 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvyTWM2OD1{Lki5PVk6KM7:TR?= MYPTRW5ITVJ?
T-24 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLXTpk{UUN3ME2yMlkyOTF{IN88US=> M1T3NXNCVkeHUh?=
NCI-H727 NW[wd4tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvUGlEPTB;Mj65NVc6PiEQvF2= M2rLOHNCVkeHUh?=
Ca9-22 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJwOUeyOVUh|ryP MVLTRW5ITVJ?
MIA-PaCa-2 M1yw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwMEC3PFEh|ryP NWLyPHlUW0GQR1XS
HT-1080 M17zPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS1cY9KSzVyPUOuNFE6QTdizszN NF3RdGdUSU6JRWK=
D-423MG NITTbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnpfppKSzVyPUOuNFc4PTNizszN M3fJS3NCVkeHUh?=
LAMA-84 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37GW2lEPTB;Mz6xN|U5KM7:TR?= M1XmcHNCVkeHUh?=
SW780 NHXYS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH2TWM2OD1|LkG0NlI6KM7:TR?= M1nINHNCVkeHUh?=
KU-19-19 NFzzbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\wUGl2UUN3ME2zMlE4ODN2IN88US=> NWe5U29IW0GQR1XS
COLO-741 M4O5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSRXNKSzVyPUOuNVg3PzNizszN MXPTRW5ITVJ?
HSC-3 NGHWcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLOTWM2OD1|LkKzNVUyKM7:TR?= M1:0RXNCVkeHUh?=
SN12C NXLvPZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3iyNmlEPTB;Mz6yOFcxOSEQvF2= M4joVXNCVkeHUh?=
786-0 M{fudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0Z2NFUUN3ME2zMlI4OjR|IN88US=> MXPTRW5ITVJ?
GAK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwM{K1OlEh|ryP M2jRSnNCVkeHUh?=
PANC-03-27 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z3Z2lEPTB;Mz6zOVA1PSEQvF2= NV;DNXRtW0GQR1XS
CTB-1 M4\O[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnBTWM2OD1|LkS3NFQ4KM7:TR?= MVjTRW5ITVJ?
A427 M3\GZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhc5NKSzVyPUOuOVk2PTZizszN Mn7uV2FPT0WU
EGI-1 M2LybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNwNkC1PFMh|ryP M2nhXXNCVkeHUh?=
U-2-OS MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLaTWM2OD1|Lk[3NlU3KM7:TR?= Mo\WV2FPT0WU
NCI-SNU-5 NWm5NHpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLZNJlKSzVyPUOuOlc4OyEQvF2= Mly4V2FPT0WU
SK-LU-1 NELwcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELMZ4xKSzVyPUOuOlg4QThizszN NVK2bVNVW0GQR1XS
697 NInhSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF30cIhKSzVyPUOuOlk3ODNizszN MVXTRW5ITVJ?
HPAF-II NVqwVHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ETWM2OD1|Lke1OFkh|ryP NES1dZdUSU6JRWK=
NCI-H2087 NHnjdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnexTWM2OD1|Lki0OlczKM7:TR?= M2LRfXNCVkeHUh?=
SK-MEL-3 NGn1PVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhUotKSzVyPUOuPFUyPTRizszN MoqyV2FPT0WU
CGTH-W-1 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[4ZmlEPTB;Mz64OVczPSEQvF2= M1fZU3NCVkeHUh?=
8505C NXrMVnNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG4dYRTUUN3ME2zMlkxODd6IN88US=> NUDZTY5IW0GQR1XS
GAMG MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRwMEKzO|ch|ryP MnyzV2FPT0WU
SW626 M1rEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrWR3dUUUN3ME20MlA1PDhizszN MX\TRW5ITVJ?
CAL-62 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwMEe0N{DPxE1? Mo\PV2FPT0WU
MHH-PREB-1 NESyW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XPR2lEPTB;ND6xNlEyOSEQvF2= MkH1V2FPT0WU
RPMI-7951 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwMkW1PFkh|ryP MVTTRW5ITVJ?
HOP-92 NHvGV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYNZBKSzVyPUSuNlU3PyEQvF2= M3nBeXNCVkeHUh?=
MDA-MB-231 M2rubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf1TWM2OD12LkK5NlI{KM7:TR?= NHXVUopUSU6JRWK=
LAN-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLrSJpiUUN3ME20MlMyPjN5IN88US=> MmPuV2FPT0WU
ALL-PO M4Dlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tSWlEPTB;ND6zOlE2PiEQvF2= MXjTRW5ITVJ?
HH NVXTVWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTRwNEG1PVch|ryP NX7OOGFKW0GQR1XS
IGROV-1 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2[3FKSzVyPUSuOFUyPzFizszN NWLvb4FJW0GQR1XS
NCI-H358 M2\EUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXxR4pLUUN3ME20MlQ2Ozh3IN88US=> MV;TRW5ITVJ?
NB5 NYTEXVA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwNkCzOlkh|ryP NIDqOW5USU6JRWK=
NCI-H747 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnsR2xKSzVyPUSuOlg5ODdizszN MYjTRW5ITVJ?
NH-12 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwN{G2NlUh|ryP NYLRXY1PW0GQR1XS
LB1047-RCC M{D0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn0cWhEUUN3ME20Mlc{QDF3IN88US=> MlLZV2FPT0WU
EFO-27 NGHGemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPtTWM2OD12Lke4OlY4KM7:TR?= NFvFUIVUSU6JRWK=
EPLC-272H MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX2Z28{UUN3ME20Mlk6PjZ7IN88US=> NIPjNVFUSU6JRWK=
CAL-54 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTVwMEK2PVUh|ryP MV;TRW5ITVJ?
H4 NHK5fZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTVwMESyOVUh|ryP NHrTPZRUSU6JRWK=
MOLT-13 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXHTWM2OD13LkC2O|c3KM7:TR?= M4\y[3NCVkeHUh?=
CAL-33 M3q2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULvUW5OUUN3ME21MlEzOzF5IN88US=> NIHYXHRUSU6JRWK=
23132-87 NHjScJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqySHJ5UUN3ME21MlE3QDd{IN88US=> MWfTRW5ITVJ?
UM-UC-3 M3rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\T[WFKSzVyPUWuNVgxPDdizszN M37YZ3NCVkeHUh?=
HuH-7 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP6U4xOUUN3ME21MlI4OTR5IN88US=> NVn3b3RrW0GQR1XS
BCPAP NEnkOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHUTWM2OD13LkOyPVY6KM7:TR?= NHXROpVUSU6JRWK=
AsPC-1 NF33eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DLUGlEPTB;NT6zOlc3OyEQvF2= Ml;pV2FPT0WU
NCI-H1155 NImxVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vC[2lEPTB;NT60NFA2OSEQvF2= NVXMRoo2W0GQR1XS
GT3TKB NHTtPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwNE[1PVgh|ryP NYXteoJ7W0GQR1XS
HCC2998 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjYOZRxUUN3ME21MlQ6OTB7IN88US=> NVzqWW5wW0GQR1XS
NUGC-3 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2NGg3UUN3ME21MlQ6OzB{IN88US=> NVuyNno{W0GQR1XS
Hs-578-T NGP1Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrJZ4pKSzVyPUWuOVM4QTRizszN M1\MR3NCVkeHUh?=
FADU MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT0TWM2OD13LkW1O|I3KM7:TR?= NYO1XJUzW0GQR1XS
NBsusSR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WyOGlEPTB;NT61O|E2PSEQvF2= NEPMcFhUSU6JRWK=
ME-180 NEPFclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXxR4ZKSzVyPUWuOVgxQTJizszN NFriUYNUSU6JRWK=
SW1710 M4Hmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn2eXVKSzVyPUWuOlE3PTRizszN MmnnV2FPT0WU
HuP-T3 M2G4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\KWGxKSzVyPUWuOlIxOjlizszN M4LwXnNCVkeHUh?=
HOS MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJTWM2OD13Lk[yPVI{KM7:TR?= M3rFZXNCVkeHUh?=
PA-1 M2LYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTRTWM2OD13Lk[0NlY2KM7:TR?= M{T2fHNCVkeHUh?=
LU-99A NVP5cpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHiNndKSzVyPUWuOlY1PTFizszN MkfMV2FPT0WU
RS4-11 NWHGTohsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7qbVBKSzVyPUWuOlY4PzVizszN NGq4UGRUSU6JRWK=
TE-8 NIPQdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfvTWM2OD13Lk[4OVM4KM7:TR?= MV;TRW5ITVJ?
RERF-LC-MS NICxOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjYe2ZkUUN3ME21MlY5QDB|IN88US=> MUjTRW5ITVJ?
MEL-JUSO NH7lWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTVwN{O3PEDPxE1? NVPlZ457W0GQR1XS
SK-MES-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfJTWM2OD13LkizOVI5KM7:TR?= NXTveWpqW0GQR1XS
D-263MG M1qzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jWPGlEPTB;NT64PFM2OSEQvF2= NVX0dnZQW0GQR1XS
NB10 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrKeWNKSzVyPUWuPFk1PiEQvF2= NWLLRpU5W0GQR1XS
SK-HEP-1 NVTJTop[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\oW5JKSzVyPUWuPVM1PzFizszN NXuzSnp[W0GQR1XS
HT-29 NX\0dIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KzbmlEPTB;NT65PFEyQCEQvF2= NHi1T|FUSU6JRWK=
KYSE-140 NYq5dmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTZwMEKxPFIh|ryP NIXMWFJUSU6JRWK=
NCI-H1666 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD14LkC4OFYyKM7:TR?= MVrTRW5ITVJ?
NCI-H1304 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJTYdDUUN3ME22MlE6QTRizszN MXvTRW5ITVJ?
RPMI-8866 NGHaN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD14LkKxN|E{KM7:TR?= MVLTRW5ITVJ?
MV-4-11 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKxSm9yUUN3ME22MlI{OTl7IN88US=> M4TRNXNCVkeHUh?=
A431 NU\vUGR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjWnBKSzVyPU[uNlQzQTZizszN MmWyV2FPT0WU
PANC-10-05 NUTuWm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jhPGlEPTB;Nj6yPFM3OyEQvF2= M1vuNnNCVkeHUh?=
TK10 NV7qbJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5[WlEPTB;Nj6zNlYxPCEQvF2= NX60VldxW0GQR1XS
NCI-H1975 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[5[YdKSzVyPU[uOFczOTVizszN NHXQfYtUSU6JRWK=
A172 M4q2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZwNEmxO|Yh|ryP NGG0N|NUSU6JRWK=
D-566MG NHj2[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDLZpVKSzVyPU[uOVQ{ODNizszN MV\TRW5ITVJ?
NCI-H2122 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjqb3dKSzVyPU[uOlE2OjhizszN MmrtV2FPT0WU
COR-L105 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\aXVNuUUN3ME22MlY2Ojd3IN88US=> NVvFepo{W0GQR1XS
AN3-CA NGrG[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mPYtKSzVyPU[uOlg3PDFizszN MVrTRW5ITVJ?
Calu-6 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD14Lke5Olk5KM7:TR?= NX\YeVV4W0GQR1XS
HCT-116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfRTmd5UUN3ME22MlgyOjZ2IN88US=> NFvFOlVUSU6JRWK=
MHH-NB-11 NH65PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHKVZhuUUN3ME22Mlg2ODB{IN88US=> NV3tV|BPW0GQR1XS
MFE-280 NYr2VYk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZwOEW5PFMh|ryP NWrQd|B1W0GQR1XS
SW1088 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTZwOUG5NVMh|ryP NYmyb|Y6W0GQR1XS
SW48 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLybmJDUUN3ME22Mlk1PTFizszN M2nHcHNCVkeHUh?=
HuCCT1 NH2yelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BbXBWUUN3ME23MlAyODN5IN88US=> MWjTRW5ITVJ?
ACHN Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHFdXF1UUN3ME23MlAzQTR|IN88US=> MWTTRW5ITVJ?
8305C NGHlV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn75TWM2OD15LkC5PVk2KM7:TR?= MYXTRW5ITVJ?
DoTc2-4510 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWw[5FsUUN3ME23MlEzOTVizszN NYPOflBFW0GQR1XS
COR-L23 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTdwMkS0NkDPxE1? MmLFV2FPT0WU
SK-MEL-30 NGiyUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\5OGprUUN3ME23MlI2ODh|IN88US=> NFXFU3dUSU6JRWK=
BE-13 NGTjeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD15LkOzPFM1KM7:TR?= NYjLT|VpW0GQR1XS
GR-ST Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Ic2lEPTB;Nz60NFE4PCEQvF2= M2LueXNCVkeHUh?=
LU-135 NFG1fHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYeycJJKUUN3ME23MlU2QTN7IN88US=> NUjW[IFUW0GQR1XS
U-266 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTdwNU[yPFYh|ryP MV3TRW5ITVJ?
NCI-H1355 M4CycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\XbGE{UUN3ME23MlU5PjN3IN88US=> MmTjV2FPT0WU
NB14 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHkPGtKSzVyPUeuOlY3PDJizszN MlXwV2FPT0WU
SCC-25 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTdwN{C5JO69VQ>? MWXTRW5ITVJ?
COLO-678 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDTWM2OD15LkexNFc3KM7:TR?= MVvTRW5ITVJ?
TGBC1TKB MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV74OIt6UUN3ME23Mlg6Ozl6IN88US=> MULTRW5ITVJ?
IST-MEL1 NHe1PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C1VmlEPTB;OD6wNFQxPiEQvF2= NYPnXVl2W0GQR1XS
ECC10 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwMEOzPVUh|ryP M2r4cnNCVkeHUh?=
EW-16 M3zTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvSoxKSzVyPUiuNFg1PDVizszN MV7TRW5ITVJ?
DOHH-2 M{i5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDtTWM2OD16LkKwNFk2KM7:TR?= NXP2cmtwW0GQR1XS
NCI-H1581 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP1fGVXUUN3ME24MlI3OzJ|IN88US=> MWLTRW5ITVJ?
TE-5 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rnNmlEPTB;OD60NlQzQSEQvF2= MlzuV2FPT0WU
CAKI-1 NVHBeWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;KTWM2OD16LkW3NlIzKM7:TR?= M13qRnNCVkeHUh?=
A673 M4nDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX60ZWNFUUN3ME24MlY{OjB{IN88US=> MkHsV2FPT0WU
CAL-12T NFXFbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4XFk{UUN3ME24MlY2PzV|IN88US=> NIjtTXpUSU6JRWK=
DBTRG-05MG M37HWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomyTWM2OD16Lke0PFU6KM7:TR?= MV7TRW5ITVJ?
SK-N-FI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwOEGzO|kh|ryP NYHjO20zW0GQR1XS
K-562 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRThwOEO5OVch|ryP MoXjV2FPT0WU
SBC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i5fmlEPTB;OD64OlY1PSEQvF2= NGTj[pBUSU6JRWK=
ES4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny2TWM2OD16Lki2PFg1KM7:TR?= NHm3WFdUSU6JRWK=
MS-1 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu4TWM2OD16Lki3OVE4KM7:TR?= M1TmRXNCVkeHUh?=
RKO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpW2lEPTB;OD64PVA2PyEQvF2= MXrTRW5ITVJ?
NCI-H1693 NEXBTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj4TWM2OD16LkmyNVch|ryP NUDiVlhvW0GQR1XS
SW954 M{TLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm3TWM2OD16Lkm2PVc5KM7:TR?= MVrTRW5ITVJ?
SK-UT-1 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7LPYFKSzVyPUiuPVc3QDNizszN NHjobHVUSU6JRWK=
T98G MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGd283UUN3ME24Mlk6QDR4IN88US=> NFTNNHlUSU6JRWK=
NCI-H2126 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G2dWlEPTB;OT6wNFgzPiEQvF2= NV;JeXVJW0GQR1XS
TE-12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrpXpJMUUN3ME25MlA{OzZ5IN88US=> NVnT[FRYW0GQR1XS
DK-MG M{fSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rmcWlEPTB;OT6yNVE6OSEQvF2= Mn\mV2FPT0WU
MEG-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u4WWlEPTB;OT6yOFk{OSEQvF2= MV7TRW5ITVJ?
HCC1937 NX7xOFd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HiUWlEPTB;OT6yPVA6OSEQvF2= M3vvfXNCVkeHUh?=
MKN45 M2\r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mzNmlEPTB;OT60OVA3PSEQvF2= M4TjTHNCVkeHUh?=
NCI-H1792 M1z0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XMWWlEPTB;OT60OVIyQSEQvF2= NYHncFVrW0GQR1XS
SW1417 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTlwNU[4N|ch|ryP MXXTRW5ITVJ?
639-V M4m2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKc2lKSzVyPUmuOlQ{QDhizszN MXnTRW5ITVJ?
P30-OHK MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJd4pKSzVyPUmuOlU{OTZizszN NVXBOnRoW0GQR1XS
YKG-1 NEexcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqyVWxvUUN3ME25Mlc2ODN|IN88US=> MYjTRW5ITVJ?
KGN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X1OWlEPTB;OT64N|c6PSEQvF2= NG\LOHVUSU6JRWK=
MSTO-211H MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnCeotIUUN3ME25Mlk2PTJ7IN88US=> M2jkRnNCVkeHUh?=
NCI-H1573 NIe0dmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH5TWM2OD1zMD6xOVc1KM7:TR?= Mn76V2FPT0WU
NCI-H720 NWrCcXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3CXnEyUUN3ME2xNE4yQTh7IN88US=> Ml73V2FPT0WU
KARPAS-45 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{myV2lEPTB;MUCuNlc6PSEQvF2= NIix[3lUSU6JRWK=
MDA-MB-175-VII MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n0TGlEPTB;MUCuOFgh|ryP NWH6PHM4W0GQR1XS
SK-NEP-1 M1rCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TPXGlEPTB;MUCuOFk5OSEQvF2= Mm\2V2FPT0WU
MKN28 NFG4U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj1TWM2OD1zMD61NVgh|ryP MojMV2FPT0WU
KYSE-520 NHzWVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pVWlEPTB;MUCuOVIh|ryP NHzKTJlUSU6JRWK=
KE-37 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzLfm9KSzVyPUGwMlUzPzJizszN NXH4OVM{W0GQR1XS
VA-ES-BJ NEn5OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFyLkW2O{DPxE1? MoKwV2FPT0WU
CCRF-CEM NUG1N21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD1zMD61Olg1KM7:TR?= MYDTRW5ITVJ?
GMS-10 M2CzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ruT2lEPTB;MUCuOlA6PCEQvF2= NFnu[ZNUSU6JRWK=
NCI-H1623 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDuTWM2OD1zMD62N|c6KM7:TR?= NVjPRWd4W0GQR1XS
NEC8 NUHiV5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFyLke3O|Mh|ryP M1;6SXNCVkeHUh?=
MOLT-16 NVLP[5VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nemlEPTB;MUCuPFEyOyEQvF2= NIrDbVFUSU6JRWK=
DJM-1 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXpbGRCUUN3ME2xNU4xOzd7IN88US=> MVrTRW5ITVJ?
U251 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HhSGlEPTB;MUGuNFQzKM7:TR?= M{fmU3NCVkeHUh?=
SBC-5 NXHzeZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzLkG0Olch|ryP NFm1W3BUSU6JRWK=
SW756 M2rqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS5TWM2OD1zMT6yNVU1KM7:TR?= M4W4R3NCVkeHUh?=
KS-1 NFXVb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfEeW1KSzVyPUGxMlI3OTlizszN NFfVZndUSU6JRWK=
SF295 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFzLkOxNFQh|ryP M13xSXNCVkeHUh?=
YH-13 NFuzZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv6T|dPUUN3ME2xNU4{OjZ5IN88US=> M4fm[3NCVkeHUh?=
SW837 NF2z[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFzLkO1NFYh|ryP NXjhUG13W0GQR1XS
KYSE-450 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFzLkSwOVch|ryP NGPITnJUSU6JRWK=
KYSE-180 NUmy[np[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfIcI5EUUN3ME2xNU41QDJizszN MljYV2FPT0WU
S-117 NWPRdmxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLzTWM2OD1zMT60PFk3KM7:TR?= NX:zcXY2W0GQR1XS
KOSC-2 NHf4V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFzLk[yNlIh|ryP M2CyO3NCVkeHUh?=
KYSE-270 NHXRNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHyUmhKSzVyPUGxMlg4PDVizszN MWHTRW5ITVJ?
D-336MG M1faO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFzLkmwO|Uh|ryP Mmn3V2FPT0WU
KALS-1 NY\2T2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF{LkCwNVYh|ryP M{TLRnNCVkeHUh?=
LB373-MEL-D MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zkPWlEPTB;MUKuNFU{OyEQvF2= NF;CSo5USU6JRWK=
HLE NUnMbZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnuSoFKSzVyPUGyMlA2QDVizszN NHvNT2hUSU6JRWK=
SJSA-1 M3vvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEeyc2dKSzVyPUGyMlA4OzVizszN M1L0b3NCVkeHUh?=
SW1990 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3nTWM2OD1zMj6wPVEyKM7:TR?= M2jhPHNCVkeHUh?=
NOS-1 M3jLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G2e2lEPTB;MUKuNVM2OiEQvF2= NVi2[2RuW0GQR1XS
GI-ME-N NIr6PGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TQT2lEPTB;MUKuNlE3OyEQvF2= NITqcnNUSU6JRWK=
NCI-H1703 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1zMj6yOlE3KM7:TR?= NXrWcVZ4W0GQR1XS
ES7 NFjGbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfoSG9MUUN3ME2xNk4zPzJ2IN88US=> NFzwN2FUSU6JRWK=
KYSE-510 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:yTWM2OD1zMj61NFc6KM7:TR?= NXTZ[4RFW0GQR1XS
BHY MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF{LkWzNFch|ryP NX;aT|ZVW0GQR1XS
TCCSUP NYXUOVNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjnTmZKSzVyPUGyMlU4PTdizszN NFH0OIRUSU6JRWK=
HSC-2 M2ntPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe0dIEzUUN3ME2xNk42QTl4IN88US=> NYPQbphMW0GQR1XS
BEN M3OwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7TTWM2OD1zMj62NVQ{KM7:TR?= NHHXcnpUSU6JRWK=
769-P NI[zcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4V5FVUUN3ME2xNk44QTJ2IN88US=> NY\SNFdPW0GQR1XS
HT Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf1[ZpKSzVyPUGyMlg{PDZizszN NX3DWoxoW0GQR1XS
LXF-289 NYfpUJpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nxSGlEPTB;MUKuPVU{OSEQvF2= M4DscXNCVkeHUh?=
OVCAR-3 M1HFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjsN5pGUUN3ME2xNk46PTZ5IN88US=> MnjnV2FPT0WU
ATN-1 M{[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnqWoFKSzVyPUGzMlAyQDRizszN NEC1bZNUSU6JRWK=
8-MG-BA M3\TOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLsTWM2OD1zMz6wOFU2KM7:TR?= NEDKN3lUSU6JRWK=
SW13 NGDm[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1izTGlEPTB;MUOuNVE3PSEQvF2= MXnTRW5ITVJ?
NCI-H1092 NX7McpNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuxS213UUN3ME2xN{4yPjJizszN NUHrR3JnW0GQR1XS
OAW-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF|LkG5N|ch|ryP MoPXV2FPT0WU
NCI-H2452 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;4XYNJUUN3ME2xN{4zOTd3IN88US=> Ml3LV2FPT0WU
CAPAN-1 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF|LkW1NVQh|ryP NEjaRYRUSU6JRWK=
NCI-H2009 NF25[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rZZmlEPTB;MUOuOVkyQSEQvF2= M2DiU3NCVkeHUh?=
SF268 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF|Lk[zNlYh|ryP MUPTRW5ITVJ?
GCIY NUn2bYJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HrNGlEPTB;MUOuOlkzPyEQvF2= NIPSOYlUSU6JRWK=
OS-RC-2 M2LpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqxc4JNUUN3ME2xN{46PTBzIN88US=> MYPTRW5ITVJ?
GCT M2LFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXOSVhwUUN3ME2xN{46Pjl5IN88US=> MWjTRW5ITVJ?
NB17 NIDwPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWxVoJKSzVyPUG0MlA5PSEQvF2= NXvTZYJRW0GQR1XS
NCI-H2030 NX\ZV2pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PLeGlEPTB;MUSuNVQ3PSEQvF2= MVHTRW5ITVJ?
HC-1 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTDZ4JKSzVyPUG0MlIxQDdizszN M1:1bHNCVkeHUh?=
QIMR-WIL MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj1TWM2OD1zND6zOFEzKM7:TR?= M1jxUnNCVkeHUh?=
Capan-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF2LkO3NVQh|ryP MX\TRW5ITVJ?
BALL-1 M3X1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO2[lhKSzVyPUG0MlQ3PjVizszN M2TaWHNCVkeHUh?=
LS-1034 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PXXGlEPTB;MUSuOlE2OiEQvF2= NGLBTHRUSU6JRWK=
U-118-MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF2Lk[zNUDPxE1? M3LMWXNCVkeHUh?=
NCI-H630 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf1PIlKSzVyPUG0MlY2PjhizszN MWHTRW5ITVJ?
OVCAR-8 NFvSWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLmTWM2OD1zND63NlAyKM7:TR?= MVPTRW5ITVJ?
NCI-H2347 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDNZYR{UUN3ME2xOE45OjNizszN NEPo[3NUSU6JRWK=
BT-549 M4fZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnuTpVKSzVyPUG0MlgzQDRizszN Mn;aV2FPT0WU
LB831-BLC NWLJcYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZNFBkUUN3ME2xOE45QTN2IN88US=> NES0[4FUSU6JRWK=
NCI-H661 M{HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF2Lkm1PUDPxE1? MWnTRW5ITVJ?
MKN7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLaTWM2OD1zNT6wNFk{KM7:TR?= M4DFe3NCVkeHUh?=
U-87-MG NXPpOmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PIVWlEPTB;MUWuNFg6PyEQvF2= MXjTRW5ITVJ?
OVCAR-4 NXS3PVBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL1RnRKSzVyPUG1MlE1OjRizszN M3jxNnNCVkeHUh?=
OE33 NIjMcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPKbVlKSzVyPUG1MlE4OTFizszN MVrTRW5ITVJ?
EC-GI-10 M1nycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF3LkKzOVch|ryP MmjFV2FPT0WU
AM-38 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrZTWM2OD1zNT6yO|E4KM7:TR?= MVvTRW5ITVJ?
NCI-H1563 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;IcGlEPTB;MUWuN|Q6KM7:TR?= NV7yRnV3W0GQR1XS
SCC-4 NHe0ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF3LkSxNFMh|ryP NWnkSmplW0GQR1XS
Detroit562 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYR2hKSzVyPUG1MlQ2PDdizszN M4\SVHNCVkeHUh?=
PC-14 M2CwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF3LkS4OlYh|ryP Mn;5V2FPT0WU
ES3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF3LkWzOkDPxE1? MXjTRW5ITVJ?
OCI-AML2 M3fxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjNTWM2OD1zNT63OlE1KM7:TR?= MnTMV2FPT0WU
LU-134-A NInjbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjRXJdKSzVyPUG1MlkxOThizszN MYDTRW5ITVJ?
SAS M3TIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDt[lRKSzVyPUG1Mlk{PzNizszN M3jQZ3NCVkeHUh?=
TGBC11TKB NUXXfoo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tpd2lEPTB;MUWuPVQyPCEQvF2= NVT5[5BtW0GQR1XS
HOP-62 M4ToPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof3TWM2OD1zNT65OVk4KM7:TR?= NWWx[lJCW0GQR1XS
G-401 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnBfIZSUUN3ME2xOU46PjR7IN88US=> M1nPVHNCVkeHUh?=
NCI-H28 NUeyeoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP6fItLUUN3ME2xOk4xQDV4IN88US=> NXOyV2doW0GQR1XS
A204 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iwTGlEPTB;MU[uNlAxPiEQvF2= MWnTRW5ITVJ?
NCI-H1299 M3qz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6bo8yUUN3ME2xOk4zOjlzIN88US=> MXvTRW5ITVJ?
VMRC-RCZ NEHPUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[zTWM2OD1zNj6yOVkzKM7:TR?= NYDwOJNNW0GQR1XS
BxPC-3 M1zMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X0WmlEPTB;MU[uNlg2PiEQvF2= M1Pvb3NCVkeHUh?=
NCI-H2228 NGfReG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvjNZJKSzVyPUG2MlUyPThizszN M4mzNXNCVkeHUh?=
NCI-H23 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDGdI5KSzVyPUG2MlYxPzhizszN NXmwd4ZmW0GQR1XS
NKM-1 NYrWWnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF5LkCxPFkh|ryP MUfTRW5ITVJ?
KYSE-70 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VdY1MUUN3ME2xO{4zQDlizszN MlzsV2FPT0WU
BB49-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fPPWlEPTB;MUeuOVY5PiEQvF2= M2W2V3NCVkeHUh?=
SCC-15 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HYU2lEPTB;MUeuPFQ4OyEQvF2= NHu3bnRUSU6JRWK=
D-247MG MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF5LkmyOFch|ryP M3:2cXNCVkeHUh?=
BB30-HNC NGrRdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF6LkCzNVgh|ryP M1G2N3NCVkeHUh?=
CAL-85-1 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[0UmV{UUN3ME2xPE4yQDB7IN88US=> NH\Qe3dUSU6JRWK=
HT-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLQcFJKSzVyPUG4MlM6PzdizszN M4PVTXNCVkeHUh?=
KYSE-410 NF7oR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjcHV6UUN3ME2xPE41PTd5IN88US=> MUDTRW5ITVJ?
SW982 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3wPYxuUUN3ME2xPE42PjR7IN88US=> MWfTRW5ITVJ?
SW962 NIPTZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjFVGFKSzVyPUG4MlU4ODJizszN NWH5RZNUW0GQR1XS
Ramos-2G6-4C10 M2HLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpTWM2OD1zOD61PVI4KM7:TR?= NYDDfmR2W0GQR1XS
OC-314 M{S0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfSS3YyUUN3ME2xPE44Ozh2IN88US=> NXK1UXVxW0GQR1XS
LS-123 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTYTWM2OD1zOD63PVAyKM7:TR?= MYTTRW5ITVJ?
D-502MG NF20TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rPdGlEPTB;MUiuPFE{QSEQvF2= NWPR[JlFW0GQR1XS
RO82-W-1 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvEeWRKSzVyPUG4MlgzQDhizszN M1;VSXNCVkeHUh?=
HuO9 M3rHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXDeGRIUUN3ME2xPU4yOzd7IN88US=> MUHTRW5ITVJ?
ETK-1 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF7LkG4Nlch|ryP M4LONXNCVkeHUh?=
SNU-387 NWHufmc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV23blI{UUN3ME2xPU4yQDh7IN88US=> MV7TRW5ITVJ?
SW1573 NFW4W|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmniTWM2OD1zOT6xPVY6KM7:TR?= M1jycXNCVkeHUh?=
NTERA-S-cl-D1 M{PhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHuZm4zUUN3ME2xPU4zODB5IN88US=> MVzTRW5ITVJ?
SF126 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojQTWM2OD1zOT6zOVAzKM7:TR?= NEXvOVRUSU6JRWK=
Calu-3 NVnpc3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLsRpdYUUN3ME2xPU41OjN5IN88US=> MYrTRW5ITVJ?
NCI-H1048 NHHMVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJyLkOyOlYh|ryP MVnTRW5ITVJ?
NCI-H226 M3PKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnn[HBKSzVyPUKwMlQ{QTlizszN Mn7UV2FPT0WU
FTC-133 NHmy[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLCepVLUUN3ME2yNE41PzB|IN88US=> M1;ic3NCVkeHUh?=
SF539 NX31Um1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzwTWM2OD1{MD61NVczKM7:TR?= NFTB[25USU6JRWK=
TE-6 NILI[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK3TWM2OD1{MD64NFY4KM7:TR?= M3LsRnNCVkeHUh?=
UMC-11 M2jNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmxTWM2OD1{MD65NVY1KM7:TR?= NHj6cGNUSU6JRWK=
Becker MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfzfXVpUUN3ME2yNU4yOTF6IN88US=> MmHmV2FPT0WU
KP-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLHTWM2OD1{MT6xNVk3KM7:TR?= MoexV2FPT0WU
ChaGo-K-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLdIU5UUN3ME2yNU4{PjJ5IN88US=> MUjTRW5ITVJ?
CFPAC-1 M3SzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHyTWM2OD1{MT6zPFU5KM7:TR?= NVvTVppZW0GQR1XS
A498 M2DtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvkOI13UUN3ME2yNU42OzF{IN88US=> NV7teGlPW0GQR1XS
NCI-H1755 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHHTWM2OD1{MT62O|QyKM7:TR?= NXvZXZBpW0GQR1XS
TI-73 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDPdoNzUUN3ME2yNk4{OjhizszN MlTqV2FPT0WU
NCI-H441 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ{LkW2PFkh|ryP MW\TRW5ITVJ?
CaR-1 NYGwZ4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;4TWM2OD1{Mz6wNlE{KM7:TR?= MY\TRW5ITVJ?
HCC1806 NEXLcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ|LkC1PFMh|ryP MnvlV2FPT0WU
SNU-449 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M333VmlEPTB;MkOuN|I6KM7:TR?= Ml3KV2FPT0WU
EKVX MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;6TWM2OD1{Mz6zPVA6KM7:TR?= M4\CPXNCVkeHUh?=
DMS-114 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:0XmlEPTB;MkOuOVc3PSEQvF2= NULUXZVjW0GQR1XS
A704 NUHxTI5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG4TWM2OD1{Mz62NVA{KM7:TR?= MV;TRW5ITVJ?
LC-2-ad NWC1NINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJ|Lk[xOFch|ryP MWfTRW5ITVJ?
VM-CUB-1 M{\hWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml61TWM2OD1{Mz63N|QyKM7:TR?= M2X2VnNCVkeHUh?=
PC-3 NELSVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMTWM2OD1{ND6wOVI3KM7:TR?= NH\RO3dUSU6JRWK=
HEL NH;3fYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;vTWM2OD1{ND6wPFY2KM7:TR?= MXrTRW5ITVJ?
ABC-1 NWnxR5FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJ2LkK3Nlkh|ryP Mki2V2FPT0WU
COLO-680N MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzD[3NKSzVyPUK0MlQ4PjRizszN MmPOV2FPT0WU
MZ1-PC NYD6XY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ2Lk[4O{DPxE1? MVzTRW5ITVJ?
NCI-H69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaTWM2OD1{ND63N|U1KM7:TR?= MV\TRW5ITVJ?
TE-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfZO|JbUUN3ME2yOU4xPDl7IN88US=> NFK5NYdUSU6JRWK=
EW-3 M4TaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ3LkGxN{DPxE1? MVrTRW5ITVJ?
PANC-08-13 M4P6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ3LkixNFMh|ryP M2DOXHNCVkeHUh?=
NMC-G1 M3Lhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUftb2I3UUN3ME2yOk4xODh6IN88US=> MVPTRW5ITVJ?
BT-20 MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ4LkS1OFMh|ryP MomzV2FPT0WU
TGBC24TKB MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH71N5NKSzVyPUK2Mlc{OzFizszN NUDRZ2U2W0GQR1XS
TE-11 NY[1T4JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC0TWM2OD1{Nj65PFk2KM7:TR?= NYPDXXNnW0GQR1XS
ESS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\PTWM2OD1{Nz6zNlE3KM7:TR?= Mo[xV2FPT0WU
JVM-3 M3npfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ5Lk[0O|Uh|ryP NUP3S25HW0GQR1XS
C3A NFHMeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ5Lki0PVYh|ryP NYHZTVZbW0GQR1XS
MDA-MB-157 NH3D[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnrVXJKSzVyPUK3Mlg4PTNizszN NH\pSmlUSU6JRWK=
KLE MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ6LkGwOVgh|ryP M1\senNCVkeHUh?=
ES1 NXLNSFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX5TWM2OD1{OD6xPFM5KM7:TR?= MWPTRW5ITVJ?
CAL-120 M1flOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ6LkO5PVkh|ryP NHj3XmtUSU6JRWK=
NCI-N87 NHPWdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon4TWM2OD1{OD61NVA2KM7:TR?= MkjEV2FPT0WU
RPMI-8226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HuRmlEPTB;MkmuNVg1OyEQvF2= MWPTRW5ITVJ?
COR-L88 NEH4dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULnc5g6UUN3ME2yPU4zPDF7IN88US=> MWjTRW5ITVJ?
UACC-893 NEHuW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXHdHd4UUN3ME2yPU4{OTN5IN88US=> NEGzWFJUSU6JRWK=
C8166 NYr4ZmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTwWHd1UUN3ME2yPU46QTl4IN88US=> MlrmV2FPT0WU
J82 NXLBOZlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNyLkixOFch|ryP M3yzOHNCVkeHUh?=
PFSK-1 NHr2PZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LHfGlEPTB;M{GuNFY2QSEQvF2= NGn2V3JUSU6JRWK=
COLO-684 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ewNmlEPTB;M{GuOFM4PCEQvF2= MVHTRW5ITVJ?
CAL-72 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIOWlKSzVyPUOxMlU4OjlizszN NXftc2I5W0GQR1XS
SNB75 NGi5RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmw[3FGUUN3ME2zNU45QTdizszN Ml;DV2FPT0WU
MDA-MB-415 M33MVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD1|MT65O|YzKM7:TR?= MnfrV2FPT0WU
SiHa NXLvc4pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXW2NKSzVyPUOyMlQ4OTFizszN NXLafog4W0GQR1XS
NCI-H1648 NV\NflV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN{LkmzOFUh|ryP NHnyZW9USU6JRWK=
EFO-21 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\mOmlEPTB;M{OuNFA2KM7:TR?= MkPGV2FPT0WU
HCC38 M1fFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoniTWM2OD1|Mz6zPFQyKM7:TR?= NFjucFNUSU6JRWK=
IA-LM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2wfnlqUUN3ME2zN{44QDh7IN88US=> Mn;TV2FPT0WU
CTV-1 NVnYb|hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fyXmlEPTB;M{OuPVc5PiEQvF2= MVPTRW5ITVJ?
NCI-H446 M2XWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC3TWM2OD1|ND6yOlg6KM7:TR?= NELqXGhUSU6JRWK=
IST-SL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TzemlEPTB;M{SuO|QxQCEQvF2= Mn3uV2FPT0WU
EW-22 NUH6cWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TpemlEPTB;M{SuO|c2QSEQvF2= NIfEO|BUSU6JRWK=
JEG-3 NE\POnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN4LkG3OlYh|ryP MYPTRW5ITVJ?
LU-65 NEPPNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN4LkK5PFUh|ryP NWexOoNbW0GQR1XS
NCI-H596 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN4Lkm1PVEh|ryP NFrJfZNUSU6JRWK=
KNS-81-FD NVfLe2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DDdmlEPTB;M{euNVQ2KM7:TR?= MYHTRW5ITVJ?
NCI-H1793 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TwfWlEPTB;M{euO|A5PiEQvF2= MlS2V2FPT0WU
NCI-H460 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrWbXVLUUN3ME2zPE4xQDd|IN88US=> NVHhUnQyW0GQR1XS
MPP-89 M1\iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN7LkW4PFYh|ryP NX23OVJ3W0GQR1XS
D-542MG MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRRmlKSzVyPUO5Mlg1OzZizszN MkHSV2FPT0WU
JAR NYnEOFU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEizPIFKSzVyPUSwMlQ4ODVizszN MWPTRW5ITVJ?
NCI-H209 M{LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRyLk[3O{DPxE1? M4\XcnNCVkeHUh?=
G-402 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjWOmZGUUN3ME20NU4{QTl|IN88US=> NEfMboxUSU6JRWK=
IST-MES1 NF\lUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5d2JoUUN3ME20Nk4yQTN3IN88US=> M3;oWXNCVkeHUh?=
Daoy MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxUGlEPTB;NEKuOVQ4OSEQvF2= NWHkOZlkW0GQR1XS
EW-11 NYPyNVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR|LkGyNVEh|ryP MVfTRW5ITVJ?
Saos-2 NEjhOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknKTWM2OD12Mz6xOVM4KM7:TR?= NUHr[WdXW0GQR1XS
no-10 M1myWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnVSGx4UUN3ME20N{4yPzB{IN88US=> NYjQVZFRW0GQR1XS
HCC1395 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3OZnJKSzVyPUSzMlQ3PDRizszN MVzTRW5ITVJ?
HCE-4 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzxSpBoUUN3ME20N{44PjZ2IN88US=> M{GyfnNCVkeHUh?=
EW-1 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR|LkiwOFkh|ryP NGO3OWdUSU6JRWK=
OCUB-M NHLVUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR2LkO2N|gh|ryP MX7TRW5ITVJ?
IGR-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR2LkSxNVUh|ryP NYT3SpE6W0GQR1XS
NCI-H1838 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHpO49KSzVyPUS0MlQ{PDlizszN MlyxV2FPT0WU
NCI-H2405 M1v1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR2LkWzOEDPxE1? NGHKb4JUSU6JRWK=
GB-1 M3zH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK4WVE3UUN3ME20OE44PDZ|IN88US=> MUXTRW5ITVJ?
MG-63 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljDTWM2OD12Nj6wOlk3KM7:TR?= M33lb3NCVkeHUh?=
KP-N-YN NWrmXFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTR4LkS2O|kh|ryP MV7TRW5ITVJ?
no-11 M1TETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTR5LkCyOFQh|ryP NYfnd4tEW0GQR1XS
SW948 NUnpOZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1dmlEPTB;NEeuN|M4PyEQvF2= MnG1V2FPT0WU
CAMA-1 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDVTWM2OD12Nz6zOFM5KM7:TR?= NXPlclJMW0GQR1XS
HCC1187 NGPTbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TobmlEPTB;NEeuOVEh|ryP MlzEV2FPT0WU
D-392MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD12Nz62OVE3KM7:TR?= MWjTRW5ITVJ?
647-V NVnkcoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDx[XRKSzVyPUS5MlM1OTRizszN M17JUXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID